Antibody-drug conjugates for H3K27M-mutant diffuse midline gliomas: prospects and challenges

Julian S Rechberger; Erica Power; Elena Millesi; David J Daniels

doi:10.4155/tde-2021-0045

Antibody-drug conjugates for H3K27M-mutant diffuse midline gliomas: prospects and challenges

Ther Deliv. 2021 Aug;12(8):553-557. doi: 10.4155/tde-2021-0045. Epub 2021 Jul 21.

Authors

Julian S Rechberger^{1

2}, Erica Power^{1

2}, Elena Millesi¹, David J Daniels^{1

3}

Affiliations

¹ Department of Neurologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
² Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN 55905, USA.
³ Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.

PMID: 34286602
DOI: 10.4155/tde-2021-0045

No abstract available

Keywords: H3K27M; antibody–drug conjugate; convection-enhanced delivery; diffuse intrinsic pontine glioma; diffuse midline glioma; efficacy; half-life; targeted therapy; theragnostic; volume of distribution.

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Brain Neoplasms* / drug therapy
Brain Neoplasms* / genetics
Glioma* / drug therapy
Glioma* / genetics
Humans
Immunoconjugates*
Mutation

Substances

Immunoconjugates

Publication types

MeSH terms

Substances

Grants and funding